VERxVE Study on Efficacy and Safety of Nevirapine XR in Comparison to Nevirapine IR With Truvada in Naive HIV+ Patients
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the efficacy of 400 mg QD nevirapine
extended release (NVP XR) formulation versus 200 mg BID nevirapine immediate release (NVP IR)
in ARV therapy naïve HIV-1 infected patients after 48 weeks of treatment. Secondary
objectives are to evaluate safety and pharmacokinetics of NVP XR and NVP IR.
Phase:
Phase 3
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Nevirapine